Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Research & Development (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Research & Development for 6 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 5.35% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, down 6.81% year-over-year, with the annual reading at $13.6 million for FY2025, 6.81% down from the prior year.
  • Research & Development hit $3.2 million in Q4 2025 for Rapid Micro Biosystems, down from $3.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.8 million in Q1 2024 to a low of $2.1 million in Q1 2021.
  • Historically, Research & Development has averaged $3.2 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Research & Development: surged 87.86% in 2021 and later decreased 13.73% in 2025.
  • Year by year, Research & Development stood at $2.9 million in 2021, then rose by 19.19% to $3.4 million in 2022, then fell by 2.5% to $3.3 million in 2023, then grew by 2.53% to $3.4 million in 2024, then dropped by 5.35% to $3.2 million in 2025.
  • Business Quant data shows Research & Development for RPID at $3.2 million in Q4 2025, $3.5 million in Q3 2025, and $3.2 million in Q2 2025.